Joany Chou v. The University of Chicago and Arch Development Corporation, and Bernard Roizman, and Aviron Company

254 F.3d 1347, 59 U.S.P.Q. 2d (BNA) 1257, 2001 U.S. App. LEXIS 15028, 2001 WL 740437
CourtCourt of Appeals for the Federal Circuit
DecidedJuly 3, 2001
Docket00-1317
StatusPublished
Cited by79 cases

This text of 254 F.3d 1347 (Joany Chou v. The University of Chicago and Arch Development Corporation, and Bernard Roizman, and Aviron Company) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Joany Chou v. The University of Chicago and Arch Development Corporation, and Bernard Roizman, and Aviron Company, 254 F.3d 1347, 59 U.S.P.Q. 2d (BNA) 1257, 2001 U.S. App. LEXIS 15028, 2001 WL 740437 (Fed. Cir. 2001).

Opinion

*1353 LOURIE, Circuit Judge.

Joany Chou appeals from the decision of the United States District Court for the Northern District of Illinois granting Bernard Roizman and Aviron Company’s motions to dismiss her claims for correction of inventorship, declaratory judgment of inventorship, fraud, breach of fiduciary duty, unjust enrichment, breach of express contract, and breach of implied contract. Chou v. Univ. of Chicago, No. 99-C4495, 2000 WL 222638, 2000 U.S. Dist. LEXIS 2002 (N.D.Ill. Feb.22, 2000) (“Chou”). Chou also seeks reinstatement of those 1 same claims against the University of Chicago (“University”). Because the district court erred in its determination that Chou did not have standing to sue for correction of inventorship under 35 U.S.C. § 256, we reverse its judgment as to that claim. We also reverse the court’s dismissal of most of her state law claims against Roizman and direct the court to reinstate certain of her state law claims against the University. However, we affirm that court’s dismissal of her breach of express contract claim against Roizman and of all her remaining claims against Aviron. We also affirm the court’s grant of Roizman’s motion to strike her allegations of academic theft and fraud. Finally, we reject Chou’s attempt to have her case reassigned to another district court judge. We therefore affirm-in-part, reverse-in-part, and remand.

BACKGROUND

Dr. Chou was a graduate student and subsequently a post-doctoral research assistant for Dr. Roizman at the University of Chicago’s Department of Molecular Genetics and Cell Biology from 1983 to 1996. Id. at *1, 2000 U.S. Dist. LEXIS 2002, at *3. Roizman is named as the sole inventor on U.S. Patent 5,328,688 and a co-inventor on U.S. Patents 5,795,713 and 5,922,328, all of which relate to herpes simplex virus and its use in an avirulent vaccine. Id. at *2, 2000 U.S. Dist. LEXIS 2002, at *5. Roiz-man is also listed as an inventor on three foreign applications: WO 9204050 (based on the subject matter of the '688 patent), WO 9833933 (based on the subject matter of the '713 patent), and PCT/US96/14292 (based on the subject matter of the '328 patent) (collectively, “the foreign applications”). The inventorship of those patents and applications is disputed.

Under University policy, inventors receive 25% of the gross royalties and upfront payments from licensing of the patents, as well as 25% of the stock of new companies that are based on their inventions. Chou allegedly told Roizman in February of 1991 that her discoveries should be patented, and he allegedly disagreed. Id. at *2-*3, 2000 U.S. Dist. LEXIS 2002, at *8-*9. At that time, however, Roizman had already filed the '688 patent application, 1 which was allegedly directed to the same disputed invention, and had named himself as the sole inventor of that subject matter. During prosecution of that application, the United States Patent and Trademark Office (“PTO”) cited two joint Chou-Roizman publications as prior art. In response, Roizman submitted a declaration stating that those publications were not available as prior art because he was the sole inventor of the work described therein and that she merely worked under his direction and supervision. Paper No. 21 at 1.

On July 14, 1992, Roizman assigned the '688 patent application to Institut Merieux, a French company that had supported the research. Id. at *3, 2000 U.S. Dist. LEXIS 2002, at *10. Just before that assignment, however, on July 1, 1992, it appears *1354 that Aviron had received an exclusive license to the herpes simplex virus technology from ARCH Development Corporation, a wholly ownéd affiliate of the University established to license and commercialize the University’s technology and intellectual property. Institut Merieux later assigned the patent application to ARCH, which in turn licensed Aviron. Id. Aviron also obtained rights to the '713 and '328 patents and the foreign applications by license and assignment from ARCH. Id. at *1, 2000 U.S. Dist. LEXIS 2002, at *3. ARCH and Roizman each own Aviron stock and have received licensing revenue from NeuroVir, the sublicensee of Aviron’s rights. Id. at *1, 2000 U.S. Dist. LEXIS 2002, at *3.

Later, in 1993, Roizman and Chou signed an agreement to share royalties from “the pending patent application to exploit the properties of the herpes simplex virus 34.5 gene.” Id. at *3, 2000 U.S. Dist. LEXIS 2002, at *11. At the time the agreement was signed, Chou and Roizman were named inventors on a patent application relating to the subject matter of that agreement, which is not in dispute in this appeal. Id. at *4, 2000 U.S. Dist. LEXIS 2002, at *12. The '688 patent application was also pending when that agreement was signed, although Chou was not then aware of its existence. Id. In 1996, Roiz-man asked Chou to resign, failing which he told her that he would fire her, allegedly because she would be in a stronger position to contest his inventorship if she were still conducting research at the University. Id. at *1, 2000 U.S. Dist. LEXIS 2002, at *3.

In 1999, Chou sued Roizman, the University/ARCH, and Aviron (collectively, “the defendants”) for correction of inven-torship under 35 U.S.C. § 256, seeking to be named as the sole inventor on the '688 patent, or, in the alternative, as a co-inventor along with Roizman. She additionally sought to be listed as a co-inventor on the '713 and '328 patents. Chou also sued for a declaratory judgment that she was an inventor on the U.S. patents and their corresponding foreign applications. In addition, Chou asserted claims of fraudulent concealment, breach of fiduciary duty, unjust enrichment, breach of express and implied contract, and academic theft and fraud.

The district court determined that Chou lacked standing to seek correction of in-ventorship under § 256 because she could claim no ownership of the patents, having surrendered all her rights to the University under an employment agreement. Id. at *2, 2000 U.S. Dist. LEXIS 2002, at *6. The court also dismissed her claim for a declaratory judgment of inventorship, finding that she had no reasonable grounds to believe that Roizman intended to file suit to settle the inventorship question.

The district court also dismissed under Fed.R.Civ.P. 12(b)(6) all of her state law claims except her count for conversion. It determined that Roizman had no duty as Chou’s advisor and department chairman to inform Chou of the status of the patent applications, and that his opinion that some of Chou’s work should not be patented, although perhaps an affirmative misrepresentation, was not fraudulent. Id. at *3, 2000 U.S. Dist. LEXIS 2002, at *9-*10.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
254 F.3d 1347, 59 U.S.P.Q. 2d (BNA) 1257, 2001 U.S. App. LEXIS 15028, 2001 WL 740437, Counsel Stack Legal Research, https://law.counselstack.com/opinion/joany-chou-v-the-university-of-chicago-and-arch-development-corporation-cafc-2001.